Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Assets (2016 - 2026)

Dexcom has reported Assets over the past 17 years, most recently at $6.6 billion for Q1 2026.

  • Quarterly Assets fell 1.75% to $6.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.6 billion through Mar 2026, down 1.75% year-over-year, with the annual reading at $6.3 billion for FY2025, 2.23% down from the prior year.
  • Assets was $6.6 billion for Q1 2026 at Dexcom, up from $6.3 billion in the prior quarter.
  • Over five years, Assets peaked at $7.5 billion in Q3 2025 and troughed at $4.9 billion in Q3 2022.
  • The 5-year median for Assets is $6.5 billion (2024), against an average of $6.3 billion.
  • Year-over-year, Assets surged 34.64% in 2023 and then dropped 3.67% in 2024.
  • A 5-year view of Assets shows it stood at $5.4 billion in 2022, then increased by 16.19% to $6.3 billion in 2023, then increased by 3.51% to $6.5 billion in 2024, then fell by 2.23% to $6.3 billion in 2025, then grew by 4.63% to $6.6 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Assets are $6.6 billion (Q1 2026), $6.3 billion (Q4 2025), and $7.5 billion (Q3 2025).